Interclean Shanghai

RADLogics AI-Powered COVID-19 solution reduces turnaround time

RADLogics AI-Powered COVID-19 solution reduces turnaround time

Moscow Center for Diagnostics & Telemedicine and RADLogics shared the results of a large-scale study (Moscow Experiment on the Computer Vision for the Analysis of Medical Images – mosmed.ai, NCT04489992) conducted by the Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department.

The clinical research found that the introduction of RADLogics’ AI-Powered solution into radiology workflow to analyze Chest-CT scans during the COVID-19 pandemic reduced report turnaround time by an average of 30 percent, which is equivalent to 7 minutes per case.

Presented by Dr. Tatiana Logunova, MD, of the Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department during the recent ECR 2021 conference, the extensive research included a total of 128,350 Chest-CT scans, of which 36,358 were processed by RADLogics AI-Powered COVID-19 solution, reported by 570 participating radiologists at over 130 hospitals and outpatient clinics in Moscow.

“In addition to finding that the integration of AI did not have a negative effect on the interpretation or report accuracy, our researchers found a significant improvement in productivity and report turnaround time by the expert radiologists that leveraged AI.”

The study was conducted over two separate phases with the first taking place between April 30, 2020 to June 18, 2020 and the second taking place between June 18, 2020 to August 31, 2020. The study found that report turnaround time was significantly shorter for all time periods in a group of radiologists with available AI results that were seamlessly integrated into radiologists’ current workflow, compared to a group with non-available AI results.

In addition, in the shift between the two study time periods, additional clinical parameters were added to the standard of care, including the addition of a disease severity score. The added information created an increased workload on radiologists, which increased the average read time by more than 25 percent. In response, the RADLogics AI-Powered COVID-19 solution was enhanced to support the new clinical requirements.

Results shown indicate that with the augmented AI solution, including all clinical measurements and severity scoring, was able to maintain the overall productivity gain of 30 percent.

“We applaud this significant real-world research by Dr. Morozov and his team, who were on the frontline of Moscow’s successful fight against the COVID-19 pandemic while demonstrating the value of embracing new AI technologies to aid in these efforts,” said Moshe Becker, CEO and Co-Founder of RADLogics.

“This study – first of its kind in its scale – demonstrates the full potential of AI as a tool to augment radiologists to increase throughput, improve efficiency and reduce time-to-treatment. This research provides large-scale clinical validation to an earlier academic study by UCLA that was published in Academic Radiology, which conducted a time-motion study using our AI-powered solution to measure the impact of our solution on radiologists’ productivity that found out using our solution saved up to 44 percent in radiologists’ reading time.”

Since the start of the pandemic, RADLogics has responded with the deployment of the company’s AI-Powered medical image analysis solution worldwide. Designed for easy installation and integration both on-site and via the cloud, RADLogics’ algorithms are supported by the company’s patented software platform that enables rapid deployment at multiple hospitals, and seamless integration with existing workflows.

In accordance with FDA guidance for imaging systems and software to address the COVID-19 public health emergency, RADLogics has made its FDA cleared CT and X-ray solutions available to hospitals and healthcare systems throughout the U.S. for patient triage and management. All the company’s AI-Powered solutions are available worldwide through major OEM distribution partners including Nuance via the AI Marketplace in the U.S. market.

“In addition to the sheer scale of this research, it is important to note the demonstrated ability of our AI-powered solution to quickly adapt to the change in clinical requirements and maintain the overall performance as demonstrated in the second phase of the study,” added Becker.

“In the near-term, responsive and scalable AI algorithms could play a critical role as healthcare systems across the world contend with potential coronavirus surges as new variants spread – not to mention the tremendous burnout and economic pressures across the healthcare sector. In the long-term, this groundbreaking research also illustrates the tremendous benefit of adopting robust AI platforms that can be deployed rapidly at scale and seamlessly integrated into existing workflows to augment radiology teams.”

Dr. Morozov’s research team from the Moscow Center for Diagnostics & Telemedicine Center included Drs. T. Logunova, A. E. Andreychenko, V. Klyashtorny, K. M. Arzamasov, and A. Vladzymyrskyy. The presentation entitled “Artificial intelligence services impact on radiologist’s performance in the context of the COVID-19 pandemic” is available for ECR 2021 registrants at https://connect.myesr.org/course/artificial-intelligence-ai-and-covid-19/.

FDA authorizes first machine learning-based COVID-19 non-diagnostic screening device

The U.S. FDA issued an emergency use authorization (EUA) for the first machine learning-based Coronavirus Disease 2019 (COVID-19) non-diagnostic screening device that identifies certain biomarkers that are indicative of some types of conditions, such as hypercoagulation (a condition causing blood to clot more easily than normal).

The Tiger Tech COVID Plus Monitor is intended for use by trained personnel to help prevent exposure to and spread of SARS-CoV-2, the virus that causes COVID-19. The device identifies certain biomarkers that may be indicative of SARS-CoV-2 infection as well as other hypercoagulable conditions (such as sepsis or cancer) or hyper-inflammatory states (such as severe allergic reactions), in asymptomatic individuals over the age of 5. The Tiger Tech COVID Plus Monitor is designed for use following a temperature reading that does not meet criteria for fever in settings where temperature check is being conducted in accordance with Centers for Disease Control and Prevention (CDC) and local institutional infection prevention and control guidelines. This device is not a substitute for a COVID-19 diagnostic test and is not intended for use in individuals with symptoms of COVID-19.

The device is an armband with embedded light sensors and a small computer processor. The armband is wrapped around a person’s bare left arm above the elbow during use. The sensors first obtain pulsatile signals from blood flow over a period of three to five minutes. Once the measurement is completed, the processor extracts some key features of the pulsatile signals, such as pulse rate, and feeds them into a probabilistic machine learning model that has been trained to make predictions on whether the individual is showing certain signals, such as hypercoagulation in blood. Hypercoagulation is known to be a common abnormality in COVID-19 patients. The result is provided in the form of different colored lights used to indicate if an individual is demonstrating certain biomarkers, or if the result is inconclusive.

The clinical performance of the Tiger Tech COVID Plus Monitor was studied in hospital and school settings. The hospital study, which was considered a validation study, enrolled 467 asymptomatic individuals, including 69 confirmed positive cases, and demonstrated that the Tiger Tech COVID Plus Monitor had a positive percent agreement (proportion of the COVID-19 positive individuals identified correctly by the device to possess certain biomarkers) of 98.6% and a negative percent agreement (proportion of the COVID-19 negative individuals identified correctly by the device to not possess certain biomarkers) of 94.5%. The school study, which was considered a confirmatory study, showed similar performance.

The Tiger Tech COVID Plus Monitor is not a diagnostic device and must not be used to diagnose or exclude SARS-CoV-2 infection. The device is intended for use on individuals without a fever. An individual’s underlying condition may interfere with the COVID-19 related performance of the device and could lead to an incorrect screening result.

Greenway Health Launches New Revenue Services Offering, GRS Select, as Ambulatory Practices Seek to Rebuild in 2021

UBERDOC Launches UBERDOC for Hospitals to Significantly Reduce Hospital Administrative Costs

Greenway Health, a leading health information technology services provider, announced the launch of its new Greenway Revenue Services offering, GRS Select™, a customizable revenue cycle management (RCM) offering designed to meet the unique, individualized needs of healthcare practices as they rebuild and improve the profitability of their practices a year after the onset of the COVID-19 pandemic.

Throughout 2020, spikes in COVID-19 cases and hospitalizations put intense pressure on healthcare staff and resources, resulting in steep declines in non-COVID-19 volume and sharply reduced revenues, with ambulatory care institutions among those most impacted. For example, recent estimates show that visits to ambulatory care providers declined by nearly 60 percent last year with primary care practices experiencing a revenue loss of $15 billion. Practices will require new resources and added support to improve financial stability in 2021. GRS Select provides a customizable solution for practices to optimize revenue by identifying new opportunities, all while simplifying existing billing practices and alleviating administrative burden for staff.

“With growing expenses and reduced revenue, healthcare providers must put a stronger emphasis on revenue cycle management in order to maintain a viable business and continue delivering the services their patients expect,” said Pratap Sarker, president. “In this current landscape, there is not a one-size fits all solution. Every practice has its unique challenges and needs. With GRS Select we are enabling today’s providers with a quality, flexible offering that improves efficiency in the most critical areas of the revenue cycle so they can get back to doing what they do best – taking care of patients.”

In contrast to most RCM services, Greenway Revenue Services partners with practices’ current staff to help them improve efficiency and customize a solution to meet their unique needs. The practice maintains full control of their billing – and through shared technology access, full visibility into the work GRS performs at any time – to give practices’ more control over their future. By ensuring consistent connection between exemplary front- and back-office functions, and through more efficient clinical workflows, a partnership with GRS will help optimize a client’s revenue cycle, while every employee in the practice is provided tools and training to understand how their tasks impact practice financial health and the bottom line.

“GRS Select allows us the opportunity to explore a more customized business partnership,” said current GRS client, Dr. Justin Vujevich of Vujevich Dermatology Associates, with three locations serving the Pittsburgh metro area. “This flexible level of service will further strengthen the efficiency of our in-house revenue cycle team while continuing to leverage the expertise of GRS, which has been an invaluable partnership to help us maintain financial stability during such a tumultuous time.”

With GRS Select, ambulatory care practices spanning primary care, cardiology, OBGYN, pediatrics and more will benefit from a flexible, customized service offering. This enables dedicated Greenway experts to service a client’s existing RCM team in any, or all, of the following areas:

  • Revenue advisory
  • Charge posting
  • Submission management
  • Insurance follow-up
  • Payment posting
  • Patient A/R
  • Patient Call Center
  • Data insights

With extensive, specialty-specific experience, Greenway’s financial care team acts as an extension of the practice to optimize people, processes, and technology to help clients achieve their goals, while never losing control over their financials. Greenway clients seeking to improve the overall health of their practice in 2021 and beyond are encouraged to complete Greenway’s free Healthy Practice Screening to determine the state of their practice’s financial health and receive a prescriptive care plan based on their results.

ABOUT GREENWAY HEALTH

Improving healthcare through innovation is at the heart of Greenway Health’s work. We provide electronic health record (EHR), practice management, and revenue cycle management solutions that help practices in multiple specialties grow profitably, remain compliant, work more efficiently, and improve patient outcomes. Our team of clinical, financial, and technology experts serve as trusted advisers, committed to our client’s success. Greenway works with over 55,000 providers across multiple specialties, which translates into millions of lives touched daily by our solutions.

 

Catalyst OrthoScience Receives FDA Clearance of Its Reverse Shoulder System

Catalyst OrthoScience Receives FDA Clearance of Its Reverse Shoulder System

Catalyst OrthoScience Inc., a medical device company focused on the upper extremity orthopedics market, has received clearance from the U.S. FDA to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.

The addition of the reverse shoulder system allows Catalyst to offer a broader shoulder portfolio and multiple arthroplasty options to shoulder surgeons across the U.S. Reverse shoulder arthroplasty is estimated to encompass more than 60 percent of the shoulder arthroplasty market.

“With the addition of our reverse shoulder system, Catalyst is now addressing the two fastest growing segments of the shoulder arthroplasty market – stemless anatomic and reverse TSA,” said Brian K. Hutchison, chairman and CEO of Catalyst. “This is beneficial for our distributors as well, who can now help surgeons more easily meet the needs of patients.”

Catalyst’s reverse shoulder system is a single-tray arthroplasty system that was engineered to combine the most beneficial and evidence-based attributes of reverse shoulder arthroplasty design. The system offers surgeon-targeted implant positioning, a streamlined and versatile system, and bone sparing implants.

The Catalyst reverse shoulder system is a total shoulder prosthesis designed for patients experiencing severe shoulder arthritis in conjunction with a grossly deficient or non-functional rotator cuff. In a reverse shoulder system, the design is inverted compared to a traditional anatomic total shoulder prosthesis where the articulating sphere is on the glenoid side of the joint and the mating insert is fixed into the humeral stem implant.

Catalyst is one of the fastest-growing players in the anatomic stemless total shoulder arthroplasty market with its Catalyst CSR™ Total Shoulder System. The Catalyst CSR system combines innovative components and unique instrumentation to bring about a precise, accurate restoration of the shoulder. It features a stemless, ellipsoid humeral component that is engineered to accurately replace the elliptical shape of the patient’s native non-spherical humeral head.

Encompass Health announces plans to build a 39-bed inpatient rehabilitation hospital in Carolina

Encompass Health announces plans to build a 39-bed inpatient rehabilitation hospital in Carolina

Boston Scientific Corporation announced it has received U.S. FDA approval of the TheraSphere™ Y-90 Glass Microspheres, developed for the treatment of patients with hepatocellular carcinoma (HCC). The approval expands access to this life-prolonging therapy for a greater number of patients, which, to date, has been utilized under a humanitarian device exemption (HDE) – an FDA classification which required institutional review board approval and limited the number of patients treated with the therapy per year. TheraSphere is now the only radioembolization technology indicated for the treatment of unresectable HCC in the U.S.

HCC is one of the most prevalent cancers in the world and the most common type of primary liver cancer, with more than half a million new global cases diagnosed annually.i The American Cancer Society estimates that approximately 32,000 new cases of HCC will be diagnosed in the U.S. in 2021.ii It is most often treated through surgery, liver transplantation, chemotherapy or embolization, including both chemoembolization and radioembolization – also commonly referred to as selective internal radiation therapy (SIRT). TheraSphere treatment, a type of SIRT with low toxicity, is comprised of millions of microscopic glass beads containing radioactive yttrium (Y-90), which are delivered directly to liver tumors via catheter and result in minimal exposure to surrounding healthy tissue.

Approval of TheraSphere was based on results from the LEGACY study, designed to evaluate the safety and efficacy of the therapy for the treatment of early and advanced HCC. The study analyzed data from 162 patients and met both primary endpoints of objective response rate and duration of response rate (72.2% at four weeks and 76.1% at six months, respectively).iii, iv,v,vi Data demonstrated 100% complete or partial patient response up to two TheraSphere treatments – disappearance of all lesions or >/= 30% decrease in target lesion diameter – and a 93% overall survival rate in patients with transplant or resection following treatment at three years.

“I am honored to have spearheaded the LEGACY trial in which we found that patients with early and advanced HCC exhibited very high response rates as well as clinically meaningful durations of response and survival, establishing TheraSphere as a standard treatment for this patient population,” said Riad Salem, M.D., M.B.A, interventional radiologist at Northwestern Memorial Hospital and principal investigator of the LEGACY trial. “The trial results, which have been accepted for publication in Hepatology, produced one of the most comprehensive databases for TheraSphere, empowering physicians to make informed, data-driven decisions for their patients.”

Treatment with TheraSphere does not require hospitalization and is typically performed as an outpatient procedure in as little as an hour, potentially alleviating pressure on healthcare systems in an increasingly complex care environment. Recognition of the benefits of SIRT – both to patients and hospitals – were reflected in recently issued guidance from the National Institute for Health and Care Excellence (NICE) when they recommended the use of TheraSphere for the treatment of patients with HCC through the National Health Service (NHS) in England, Wales and Northern Ireland.

“The FDA approval and the recent NICE recommendation will expand access to TheraSphere, which has demonstrated improvement in both survivability and quality of life through 20 years of clinical trials and real-world outcomes in the more than 70,000 patients globally,” said Peter Pattison, president of Interventional Oncology, Peripheral Interventions, Boston Scientific. “We expect to continue to focus our efforts on bringing this treatment to more patients, both by planning a randomized trial to study the combination of TheraSphere and immunotherapy in patients with HCC not eligible for curative treatments, as well as further investigating the therapy for different cancer segments, including prostate and brain.”

About Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.

Vyne Medical Auto-Indexing Solution Now Available to Hospitals and Health Systems

Vyne Medical Auto-Indexing Solution Now Available to Hospitals and Health Systems

Vyne Medical®, a leading provider of electronic health information and communication management solutions, announces the launch of new functionality to help streamline hospital administrative functions. Auto-indexing accurately transforms documents and unstructured patient information into structured, shareable data for use across health systems.

Part of Vyne Medical’s Trace® platform, Auto-indexing technology leverages advanced machine learning and form recognition technology to read incoming text and map it to targeted fields in Trace. Demographic information contained in high-volume forms such as physician orders, insurance forms and patient registration forms is automatically classified and pre-populated into the appropriate patient record fields.

“Vyne Medical remains dedicated to helping hospitals and health systems improve the way they capture and share information to ensure a more complete patient record, create workflow efficiencies and recover lost revenue,” said Marcy Tatsch, president of Vyne Medical. “Auto-indexing accomplishes these key objectives by quickly transforming documents into structured, reliable data.”

Hospitals using Vyne Medical’s Auto-indexing functionality are able to process incoming documents immediately without hand-keying information. This leads to time savings, productivity increases and cost reductions.

“By reducing the burden of manual data entry, our Auto-indexing solution creates workflow efficiencies while reducing the incidence of human error,” said Ruchi Medhekar, senior vice president of strategy and platform at Vyne Medical. “These advantages give hospitals the opportunity to elevate service levels, reduce overtime expenses, improve patient throughput, and enhance financial outcomes.”

One hospital using Auto-indexing has experienced record lows in its abandoned call percentage and hold times, a 40-percent improvement in order processing time and the elimination of its backlog of open orders. Another hospital reported a 50-percent time savings in order reconciliation and a 3-week reduction in the hospital’s order backlog. The impact result includes elimination of paid overtime and an increase in patient outreach for procedure scheduling.

 

About Vyne Medical

Vyne Medical is a recognized industry leader in send-to-end health information exchange and electronic healthcare communication management. The company’s robust technology platform facilitates the electronic capture, storage and submission of healthcare data in virtually any form – voice, fax, image, data or electronic document. Vyne Medical’s solutions connect disconnected data to close gaps in documentation and improve the continuum of care through a more complete and fully accessible patient record. Outcomes include improved financial strength, operational performance and patient experience.

 

Olive Health Technology and bluum Enter Strategic Partnership to Augment Mental Health Services

 Olive Health Technology and bluum Enter Strategic Partnership to Augment Mental Health Services

Olive Health Technology has collaborated with blüüm, an integrated health platform, to launch Ollie, an AI solution inspired by talk therapy to make mental health-related self-care more accessible for today’s fast-paced, stressful lifestyle. The fully automated conversational chatbot is backed by principles of clinical psychology, behavioral science, and neuroscience.

Mental health issues are on the rise, especially among many employees who have been forced to work from home and are feeling isolated or experiencing Covid-19-induced burnout. Olive Health Technology and blüüm aim to address this major public health concern with Ollie, a personal robot friend that provides in-the-moment emotional support and guides users through a series of wellness strategies that fits their personal needs.

“While Ollie is not a medical product, we expect to see a 30% reduction in anxiety and depression after two weeks of use. We’re excited to partner with one of the most innovative insurtech companies to help people manage their health holistically,” said Wenjue Wu, Founder of Olive Health Technology.

“The pandemic has a significant impact on the mental well-being of people in Hong Kong. At blüüm, we believe in the importance of holistic health, and it is our priority to offer all-round care for the community to satisfy their different health needs. Our partnership with Olive Health Technology enables us to offer more accessible and regular mental health support,” said Ying Wu, CEO of blüüm.

blüüm is offering this anonymous mental health service for people to voice their feelings around work and life as well as to build a long-term relationship over time. Ollie is now available via blüüm’s Facebook page.

About blüüm

Established in 2020, blüüm is an augmented health platform that provides innovative insurance and medical solutions to help users live their life to the fullest. It works closely with its strategic insurtech partner, The CareVoice, and top-tier insurance companies to provide user-centric and diversified health insurance solutions. With the creative use of technology and an inventive approach to health management, blüüm eliminates the pain points of the traditional insurance industry and provides a seamless healthcare experience to every user.

Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test

Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test

Aptamer Group, the developer of diagnostic and therapeutic Optimer reagents, announced a commercial partnership with Mologic, a leading developer and manufacturer of lateral flow and rapid diagnostic tests. The partnership will work towards CE marking of Aptamer Group’s AptaDx SARS-CoV-2 lateral flow rapid antigen test for professional use, to detect the SARS-CoV-2 spike protein antigen in anterior nasal swabs. Initial test analysis with laboratory samples has demonstrated excellent sensitivity being able to detect as little as 1000 virus particles per mL, with further clinical validation to support the CE marking to be performed at the Integrated COVID Hub North East in Newcastle, UK.

Testing of the Optimer reagents has shown that they recognise the original viral strain and the dominant emerging variants. These variants are the ‘Kent’ variant, B.1.1.7, the Danish variant, D614G, and the South African variant, B1.351 (also known as 501Y.V2).

Working with Mologic will help to accelerate the development of Aptamer Group’s test to market and provide Aptamer Group with manufacturing capacity through Mologic, in addition to other partners, for the final commercialized test. Aptamer Group is involved in ongoing discussions with other global manufacturers to access additional capacity for the delivery of several million tests per month.

Aptamer Group’s SARS-CoV-2 rapid antigen test will be the first aptamer-based diagnostic test to be commercialised. Aptamers are synthetic nucleic acid-based affinity reagents, produced by solid phase synthesis offering simple, scalable, and highly cost-effective affinity solutions. The production of aptamers compared to standard protein-based affinity reagents offer significant cost advantages, allowing large scale development and delivery of tests globally, including to low- and middle-income countries.

Further updates will be provided following the completion of the clinical evaluation of the test performance.

Dr Arron Tolley, CEO of Aptamer Group, commented: “‘Following our initial collaboration with Mologic to develop the AptaDx SARS-CoV-2 rapid antigen test over recent months, I am delighted to have now extended our partnership to progress the CE marking of Aptamer Group’s test. We have seen encouraging laboratory performance of the rapid antigen test and have demonstrated the detection of the current main SARS-CoV-2 variants. We are now keen to take the test through clinical evaluation with Newcastle’s Integrated COVID Hub to support the CE marking with Mologic. I look forward to updating the market on clinical and commercial progress in due course.”

Mark Davis, Chief Executive Officer of Mologic, said: “The agreement with Aptamer Group further demonstrates our commitment to efforts tackling the COVID-19 pandemic, globally. In doing so, Mologic and our partners are able to offer an accelerated route to market, with increased manufacturing capacities, to crucially support expanded access to these rapid test technologies.”

Aptamer Group is a world-leading provider of Optimer™ reagents for use in research, diagnostics and therapeutics. The Company strives to deliver transformational solutions, that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology.

Optimers are next-generation aptamer molecules derived from nucleic acids that function as an antibody alternative. Despite many well-recognised problems with antibodies, the global antibody market is currently worth over $130Bn. Optimers are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

At Aptamer Group, we have successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through our unique technology and processes, we enable scientists and collaborators to make faster, more informed decisions that support discovery and development across the Life Sciences.

Mologic is a leading developer of advanced lateral flow and rapid diagnostic technologies. Leveraging its core technology platforms, the Company works with global organisations, researchers and clinicians to help them deliver fast, reliable and accurate diagnosis at the point-of-need. Mologic’s founder, Professor Paul Davis, was one of the co-inventors of the Clearblue pregnancy test that was launched in 1988 as the world’s first commercial application of lateral flow technology. The creativity, insight and knowledge that led to that ground-breaking invention has guided Mologic since its formation in 2003.

Mologic offers world-leading technology and scientific research expertise for contract research and development, alongside a portfolio of device and reagent products for clinical applications. The Company also helps organisations to scale-up manufacturing from initial prototyping through low to mid-scale production. Mologic’s science has broad application across markets and disease states where rapid, accurate point-of-need testing can help make a difference in patient care and patient outcomes.

Clients include the Bill & Melinda Gates Foundation where Mologic is leveraging core technology through its Centre for Advanced Rapid Diagnostics (CARD) to develop the next-generation of ultra-sensitive point-of-need diagnostics which are easy to use and low cost to manufacture – critical to the success of many global health programmes.

The Company is actively seeking strategic partners for its internal pipeline of respiratory, infectious disease and women’s health diagnostics.

Mologic is headquartered in Bedford in the United Kingdom and has a US subsidiary in the greater Boston area, MA, USA.

 

3 Considerations After A Car Accident

Getting injured in a car accident can be a frustrating experience. Depending on the extent of your injuries, this whole situation can impact your life physically, financially, and mentally. However, there are plenty of things you can do to protect your rights and interests.

So, if you want to ensure you’re dealing with this kind of situation properly, below are the three considerations you should make after a car accident:

  1. Seek Medical Attention For Your Injuries

In most cases, serious injuries as a result of motor vehicle accidents don’t become immediately apparent. There are instances you’ll feel the pain a day or two following the collision. That’s why unless you’re sure you’re not injured, you should seek immediate medical attention to avoid complications in the long run.

Even if the crash comes with a minor impact, you may still sustain a permanent injury that can affect your life forever.

Also, by getting yourself checked by a doctor, you can have easy access to your medical records which are crucial when you decide to file a claim for the recovery of compensation.

  1. Hiring A Lawyer

Typically, seeking compensation for the injuries caused by a car accident is never an easy process. With all the things that need to be considered from the get-go, you need to hire a reputable and experienced lawyer to help you navigate your situation.

The following are the things your lawyer can do for your case:

  • Assess the facts of your case and determine the legal options available to you.
  • Help you understand what your rights are and how you can get the most out of it for your situation.
  • Help you collect pieces of evidence, especially when it comes to determining the true value of your claim.
  • Negotiate with the insurance company to make sure you get a fair settlement for all your injuries.
  • Help file a personal injury lawsuit in court in case the insurance negotiation fails despite earnest efforts to settle.
  • Prepare and submit all the paperwork within the required time limit. In law, there is what is called the statute of limitations. This refers to the allowable time frame where a victim can validly file a claim against the negligent perpetrator. Specifically, Peddicord & Townsend’s published an article regarding the statute of limitations for medical malpractice cases in Missouri. And similar to medical malpractice cases, you also need to observe the time limits when initiating a car accident case in court.
  1. Documentation

If possible, you should get the facts of your car accident immediately through documentation. By documenting what happened, you’ll be able to obtain essential pieces of evidence which can help you prove the liability of the at-fault party.

To get started, you should get the name, contact number, and address of all the parties involved in the collision. You should also ask information about the insurance of the other driver. If there are relevant witnesses, find time to get their information for future use.

Lastly, don’t forget to secure photos of the accident scene, damage to your vehicle, your injuries, police reports, and medical records.

Wrapping Up

Surviving an automobile accident is no easy feat. If you don’t know what to do after sustaining injuries, you may not be able to protect your rights and interests as well as recover the right amount of compensation you deserve. Therefore, to maximize both your physical and financial recovery, remember the three main considerations above and you’ll be able to get your normal life back in no time.

5 Reasons You Might Claim Victim Compensation

5 Reasons You Might Claim Victim Compensation

The US, including all of its territories, operates a compensation program for crime victims. The program’s goal is to provide financial assistance for violent or personal crime victims. Crime victim compensation also exists in some other countries.

Convicted perpetrators of crimes pay fees to the court in most US states. The payments serve as a revenue source for the victim compensation program. The federal government also provides support to each state’s program through the Victims of Crime Act (VOCA).

The total amount of cash that crime victims may receive depends on the state’s compensation cap. Each category of crime-related expense may also have a limit in terms of the money that can be paid out to the victim.

Have you or a family member been a victim of a crime?  Below are five reasons you might claim victim compensation.

  1. Get Reimbursement For Your Medical Expenses

Some form of medical treatment is necessary for many crime-related injuries. Some injuries even require a long-term care plan, like those who contracted illnesses as a result of the 9/11 terrorist attack.

If you or a family member is one of the 9/11 first responders who were exposed to toxic dust and fumes from the collapsed buildings, you can find a resource online that provides information about how you can claim compensation.

The good news is that crime victims’ compensation programs take into account both current and future medical expenses a crime victim suffers as a result of the crime committed against them.

Medical costs that the compensation program covers include chiropractor, prescriptions, surgeries, physical therapies, emergency room visits, hospital stays, x-rays, and even massage therapies.

  1. You Need To Undergo A Mental Health Therapy

Most crimes can cause victims to experience ‘mental anguish.’ It’s discomfort and suffering outside of the physical pain a victim already experiences.

If the crime committed against you has had a negative impact on you psychologically, you might need to submit yourself to psychological therapy. Mental health programs help alleviate stress, depression, fear, and sleeplessness that may result from your experience as a crime victim.

The problem is that psychological therapies can be expensive because they involve a series of sessions with a psychologist. Fortunately, crime victim compensation also covers mental health expenses.

  1. Replace Lost Income

Crime victims are also entitled to receive compensation for any lost income because of their injury. For example, if the crime’s perpetrator broke your ankle and you couldn’t go to work, you can get reimbursement for the total wages you would’ve earned from your job during the entire period your injury prevented you from performing your work duties.

Note that you’re also entitled to compensation if the injury you’ve sustained results in any disability that will reduce your ability to earn in the future.

  1. Your Personal Property Was Damaged

If the crime caused damage to your personal property, you could use the compensation money for repairs. This type of loss is common in burglary cases. Covered property damages are broken exterior windows, as well as destroyed door and window locks.

  1. Continue To Provide Support To Your Dependents

Family members of a person who got seriously injured or died because of a crime committed against them may be able to apply for a dependency compensation claim. It’s for the loss of financial support resulting from your injury or death.

The crime victim compensation program calculates the compensation for financial support loss by determining the income, including the government pensions or benefits, that you’ll lose from the time you got seriously injured or died. The amount you would’ve used for your own personal expenses will then be deducted from your total income. What’s left may be awarded as compensation for your dependents’ financial support.

Final Thoughts

Those are the most common reasons why people apply for victim compensation. Note that you’re eligible for it if you’re a victim who got injured or died because of a crime. Someone who was injured or died after coming to the aid of a victim is also eligible.  It’s the same case for a first responder to a crime.

Translate »